In this study, we observed that ASCs affected by metabolic syndrome exhibited a significant reduction in their chondrogenic potency as characterized by a collapse of the Sox9 gene transcription and a consequent downregulation of the related cartilaginous factors. The gene discussed is SOX9; the disease is metabolic syndrome.